-

CODX INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against Co-Diagnostics, Inc. and Encourages Investors to Contact the Firm Before August 17

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of Utah on behalf of those who acquired Co-Diagnostics, Inc. (“Co-Diagnostics” or the “Company”) (NASDAQ: CODX) securities during the period from February 25, 2020 through May 15, 2020. Investors have until August 17, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The lawsuit alleges that the Company made materially misleading statements that its Covid-19 tests were 100% accurate—a staggering claim that appeared to set Co-Diagnostics apart from other competitors developing Covid-19 tests.

On May 14, 2020, news outlets reported that Co-Diagnostics was reticent to participate in U.S.-based testing to verify its accuracy claims, casting doubt on Co-Diagnostics’ claims of 100% accuracy. On this news, shares of Co-Diagnostics fell $1.29, or 5.5%, to close at $22.13 per share on May 14, 2020.

On May 14, 2020, after the markets closed, financial news services began reporting that the U.S. Food and Drug Administration announced publicly that no Covid-19 test is 100% accurate, undermining Co-Diagnostics’ claims about its tests’ perfect accuracy. On this news, shares of Co-Diagnostics fell $5.06, or 22.9%, to close at $17.07 per share on May 15, 2020.

If you acquired Co-Diagnostics securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
(212) 371-6600
investigations@kmllp.com
www.kmllp.com

Kirby McInerney LLP

NASDAQ:CODX

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
(212) 371-6600
investigations@kmllp.com
www.kmllp.com

Social Media Profiles
More News From Kirby McInerney LLP

JEFFERIES FINANCIAL GROUP, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Jefferies Financial Group, Inc. (“Jefferies” or the “Company”) (NYSE:JEF). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On June 25, 2026, Jefferies reported quarterly results showing weaker asset-management fees a...

ALIGNMENT HEALTHCARE, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (NASDAQ:ALHC). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On July 8, 2026, it was reported that a former executive at Alignment Healthcare fil...

UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On June 30, 2026, Unicycive announced that the FDA had issued a second Complete Response Letter (“CRL”) reg...
Back to Newsroom